Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) – Pipeline Review, H2 2016’, provides in depth analysis on Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted pipeline therapeutics.

The report provides comprehensive information on the Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B)

The report reviews Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics and enlists all their major and minor projects

The report assesses Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc.

Allergan Plc

Azevan Pharmaceuticals, Inc.

Laboratorio ELEA S.A.C.I.F. y A.

Orphan Therapeutics, LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) Overview 6

Therapeutics Development 7

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Products under Development by Stage of Development 7

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Products under Development by Therapy Area 8

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Products under Development by Indication 9

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Products under Development by Companies 12

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Companies Involved in Therapeutics Development 21

AbbVie Inc. 21

Allergan Plc 22

Azevan Pharmaceuticals, Inc. 23

Laboratorio ELEA S.A.C.I.F. y A. 24

Orphan Therapeutics, LLC 25

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Drug Profiles 26

A-988315 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

ABT-436 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

AVN-628 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

desmopressin acetate - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

desmopressin acetate - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

PHT-103 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecule to Antagonize Vasopressin V1b Receptor for Depression - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

terlipressin - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

terlipressin - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Dormant Projects 37

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Discontinued Products 38

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) - Featured News & Press Releases 39

May 08, 2016: Studies Demonstrate New Options to Help Prevent and Treat Nocturia 39

May 03, 2016: Allergan Presents New Data on SER120 at the American Urological Association Meeting in San Diego 40

Jan 04, 2013: FDA Grants Orphan-drug Designation For New Terlipressin Formulation For Treatment Of Ascites 40

Apr 23, 2012: Ikaria Obtains Approval For LUCASSIN In Australia 41

Nov 30, 2010: Ikaria Begins Enrollment Of Pivotal Trial For Lucassin 41

Mar 30, 2010: Ikaria Acquires New Drug Application For Lucassin 42

Mar 30, 2010: Ikaria Acquires North American Rights To Lucassin From Orphan Therapeutics 43

Jun 12, 2009: FDA Accepts Final Section Of NDA Filing For Lucassin 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by AbbVie Inc., H2 2016 21

Pipeline by Allergan Plc, H2 2016 22

Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 23

Pipeline by Laboratorio ELEA S.A.C.I.F. y A., H2 2016 24

Pipeline by Orphan Therapeutics, LLC, H2 2016 25

Dormant Projects, H2 2016 37

Discontinued Products, H2 2016 38

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Mechanism of Actions, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared